Recently, SCIEX CE and biopharmaceutical business division released a new product - biological product analysis system C100HT.
Conference site
High-performance capillary electrophoresis device, referred to as capillary electrophoresis device (CE), uses a capillary as a separation channel, and uses a high-voltage DC electric field as a driving force. It utilizes the difference in the mobility between charged particles and the difference in distribution coefficient to separate it. Another major advancement after the phase chromatograph has led to a wide range of analytical sciences from micro upgrades to nano upgrades.
For CE, the most important market is the biopharmaceutical field, especially in the field of new drug development. The commercialization process of biological products includes three stages of discovery/screening, clinical, and commercialization. Hundreds to thousands of clones go through these three At the end of the stage, only one commercial product was formed. The whole process used many analytical methods. From the perspective of separation, CE is the most effective and fastest method for biopharmaceutical research.
In the discovery/screening phase, two steps are mainly performed: cloning screening and cell culture optimization. In these two steps, the analysis of the sugar spectrum can predict the effectiveness of the drug and help optimize cell culture conditions. However, the current clonal selection process In the initial screening of 100% of potential clones, the concentration was determined by titer to determine the presence or absence of protein; when selecting a partially screened clone for secondary screening, it was only possible to select due to the large sample size and lack of effective screening techniques. Some of the primary screening clones were used for secondary screening. Therefore, because the screening technology could not meet the requirements, a large number of potentially available clones were discarded after titer screening. In order to solve this problem, only all potential clones were subjected to sugar screening and identification was improved. The possibility of an effective molecule, in order to make a better decision. That means that the biopharmaceutical industry is in urgent need of high-throughput, rapid sugar-based analytical techniques.
The challenge for glycosyl analysis, which is to test more cell culture conditions and cloned samples, is to solve the problem of time first. For example, simplification of complex and time-consuming sample preparation, separation and data analysis.
In response to this urgent need, SCIEX CE has launched a new product, the biological product analysis system C100HT. According to reports, C100HT's value proposition is a qualitative, high-throughput, fast sugar-based analysis platform for biopharmaceuticals. Clonal screening and cell culture conditions are optimized. This phase requires rapid generation of results and elimination of bottlenecks associated with large-capacity sugar-based screening.
Photos of SCIEX CE and biopharmaceuticals global and Chinese leadership and new C100HT
The C100HT pre-treatment reagents are designed specifically for use with automated workstations. The time required to automatically process 96 samples is only 1.5 hours, although manual processing is also possible. The time required is less than 3 hours. C100HT achieves high-throughput analysis, separation 96 Only 2.5 hours for each sample. The data analysis is automatic, fast, and intuitive. Immediately after the separation of 96 samples of analytical data is completed, the emergence of C100HT enables high-throughput screening of biopharmaceutical production processes.
Regarding the significance of the launch of the new product C100HT to Chinese users, Dr. Xu Wei, Senior Manager of SCIEX's China Separation Business Operations and Maintenance Department said that we can use a very simple sentence to describe, 'Let our customers use even better weapons.' Find more medicine faster.